A clinical trial is something that can be offered at any part in the bladder cancer journey, from initial suspected diagnosis, through investigations and different treatment, and in later follow-ups, or at the end of life.
A clinical trial can be offered at any stage in the bladder cancer journey, from initial diagnosis, through investigations and different treatments to later follow-ups or even the end of life.
There are a number of clinical trials in bladder cancer. These usually compare a new treatment which has the potential of working better or with less side effects, with what is used as the “gold-standard”.
Different trials are available in different hospitals. This is because of either the complexity of the trial or because of the type of treatment or test involved. For example, studies of surgery or radiotherapy may only be open at the particular hospital or cancer centres where the operation or the radiotherapy takes place. All studies have particular tick boxes to confirm whether this study is the correct one for you and your cancer. It may be that you and your type of bladder cancer do not match the eligibility criteria (or check list) for the study.
You should ask your doctor if you are suitable for a clinical trial. It is always helpful to take information with you for any trials that your doctor may not be familiar with. If the study is open elsewhere in the UK and it looks as though you may be eligible for this (and are prepared to travel), you could ask your doctor to refer you.
If you have been affected by bladder cancer and would like to take part in research to improve services, please complete our sign-up form and we'll be in touch with opportunities to take part in various studies.
You can find a full list of open clinical bladder cancer trials in the UK below.
Current Open Bladder Cancer Trials
Suspected bladder cancer
The purpose of this study is to investigate the feasibility of using ctDNA to support cancer diagnosis and risk stratification where tissue biopsy is challenging due to infection risk, technical impracticalities and resource limitations.
Location: Royal Marsden Hospital Sutton, Surrey
ClinicalTrials.gov ID: NCT04566614
This trial will need a urine sample from participants who are under investigation for possible bladder cancer and are due to undergo a standard of care investigative cystoscopy and biopsy. This study is testing to see whether the UroX biomarker can be detected in urine samples and therefore be a way of diagnosing patients. Both healthy volunteers and bladder cancer participants are needed.
Location: East and North Hertfordshire NHS Trust
ClinicalTrials.gov ID: NCT03973307
Non-muscle-invasive bladder cancer
The purpose of this study is to evaluate recurrence-free survival in people treated with erdafitinib compared to their doctor’s choice, for people with high-risk non-muscle-invasive bladder cancer who harbor FGFR mutations or fusions, and who recurred after BCG therapy.
Locations: Christie Hospital Manchester, University of Sheffield Teaching Hospitals, Lister Hospital Stevenage
ClinicalTrials.gov ID: NCT04172675
This study is for people who have high-risk non-muscle-invasive bladder. Patients will receive BCG, with the possible addition of the immunotherapy sasanlimab. This is a study looking at how well sasanlimab works together with BCG in people with bladder cancer.
Locations: Barts Health NHS Trust, Charing Cross Hospital
ClinicalTrials.gov ID: NCT04165317
This study is for people who have high-risk non-muscle-invasive bladder cancer that is persistent or recurrent following BCG induction. Patients will receive a drug called pembrolizumab along with BCG, or BCG without pembrolizumab. This is a study looking at how well pembrolizumab works together with BCG in people with bladder cancer.
Locations: Raigmore Hospital, St Bartholomew’s Hospital, St Georges University Hospitals NHS Foundation Trust
ClinicalTrials.gov ID: NCT03711032
RESECT aims to be the largest multicentre international observational study evaluating the first and most important step in the management of non muscle-invasive bladder cancer (NMIBC), the transurethral resection of bladder tumour (TURBT).
ClinicalTrials.gov ID: NCT05154084
The purpose of this study is to evaluate the overall complete response rate in participants treated with TAR-200 in combination with cetrelimab or TAR-200 alone, or cetrelimab alone with Carcinoma in Situ (CIS).
Locations: Glasgow, Leeds, Manchester, Sheffield
ClinicalTrials.gov Identifier: NCT04640623
Muscle-invasive, advanced or metastatic bladder cancer
This study is for people with muscle-invasive bladder cancer. This study is looking at whether a type of immunotherapy drug called durvalumab can be safely administered after initial treatment. This study is to determine whether durvalumab given after standard trimodality therapy (maximal transurethral resection of the bladder tumour (TURBT) followed by concurrent chemotherapy and radiation) improves disease-free-survival when compare to surveillance alone.
Locations: Royal Cornwall Hospitals NHS Trust, The Christie NHS Foundation Trust, The Royal Marsden NHS Foundation Trust – Sutton, University Hospital Southampton NHS Foundation Trust, Imperial College Healthcare NHS Trust – Charing Cross, Royal Devon University Healthcare NHS Foundation Trust, Nottingham University Hospital NHS Trust
ClinicalTrials.gov ID: NCT03768570
This study is for people with locally advanced or metastatic urothelial cancer. It is a randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab immunotherapy.
Location: Queen Mary University of London
The investigators would like to test stool samples of patients with womb, cervix or bladder cancer having pelvic radiotherapy to see if there are differences in the number/type of gut bacteria between those who get severe bowel symptoms compared to those with mild bowel symptoms. They also want to see whether these differences in gut bacteria can tell who will develop severe bowel symptoms during or after radiotherapy and determine the effect of diet.
Location: Wythenshawe Hospital Manchester
ClinicalTrials.gov Identifier: NCT04995809
This is a study for people with advanced bladder cancer who test positive for the FGFR biomarker. Patients will receive either a drug called derazantinib, or both derazantinib and another drug called atezolizumab. This is a very early study looking at the safety and ideal dose of derazantinib.
Locations: Barts and The London, The Sarah Cannon Research Institute London, University College London Hospitals, The Royal Marsden NHS Foundation Trust, Sutton
ClinicalTrials.gov ID: NCT04045613
This study is looking at the drug RP1 alone and then RP1 in combination with nivolumab. This trial needs participants with advanced and/or refractory solid tumours. This a phase 1 and phase 2 trial and is being done to determine the maximum tolerated dose and recommended dose of the drug. It is for a range of cancers and includes bladder cancer.
Locations: University of Leeds- Teaching Hospital, Oxford University Hospitals NHS Trust, Beatson West of Scotland Cancer Center Glasgow, The Clatterbridge Cancer Centre NHS Foundation Trust Bebington, Royal Marsden Hospital London
ClinicalTrials.gov ID: NCT03767348
This is a study for people with high-risk muscle-invasive bladder cancer and who have had a cystectomy. Patients will be followed up closely after their cystectomy and may receive the immunotherapy atezolizumab. This is a phase 3 study looking to see if atezolizumab can improve disease-free survival.
Locations: Belfast City Hospital, Addenbrookes Hospital, Western General Hospital, St James Hospital, Barts Hospital, University College London NHS Foundation Trust, Derriford Hospital, Royal Preston Hospital, Weston Park Hospital, Southampton University Hospitals NHS Trust, Royal Marsden Hospital (Sutton).
ClinicalTrials.gov ID: NCT04660344
JAVELIN Bladder Medley
This study is for people who have locally advanced or metastatic bladder cancer, who have responded to chemotherapy. The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.
ClinicalTrials.gov ID: NCT05327530
This study is for people who have muscle-invasive bladder cancer. Patients will receive a drug called pembrolizumab along with chemotherapy and bladder removal, or chemotherapy and bladder removal without pembrolizumab. This is a study looking at how well pembrolizumab works together with chemotherapy and surgery in people with bladder cancer.
Locations: Aberdeen Royal Infirmary, Torbay Hospital, Kent and Canterbury Hospital, Lister Hospital, The Royal Marsden Foundation Trust, Imperial College Healthcare NHS Trust, Norfolk & Norwich University Hospital NHS Foundation Trust, Royal Cornwall Hospital.
ClinicalTrials.gov ID: NCT03924856
This study is for people who have muscle-invasive bladder cancer, and who are not eligible for cisplatin-based chemotherapy. Patients will receive either surgery alone, pembrolizumab plus surgery, or enfortumab vedotin plus pembrolizumab plus surgery. This is a study looking at how well pembrolizumab and enfortumab vedotin work together with surgery in people with bladder cancer.
Locations: Kent and Canterbury Hospital, Lister Hospital, Barts Health NHS Trust, The Royal Marsden Foundation Trust, Imperial College Healthcare NHS Trust, Western General Hospital, Royal Cornwall Hospital
ClinicalTrials.gov ID: NCT03924895
This study is for people who have muscle-invasive bladder cancer. Patients will receive chemoradiotherapy, and might also receive a drug called pembrolizumab. This is a study looking at how well pembrolizumab works together with chemoradiotherapy in people with bladder cancer.
Location: South Devon Healthcare Foundation Trust
ClinicalTrials.gov ID: NCT04241185
A registry facilitating implementation of the MRI guided Linear Accelerator radiation therapy system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.
Locations: London, Manchester
ClinicalTrials.gov ID: NCT04075305
For people who have advanced or metastatic bladder cancer, who have progressed during or following chemotherapy. Patients will receive a drug called atezolizumab, and perhaps one of the following drugs: enfortumab vedotin, niraparib, Hu5F9-G4, isatuximab, linagliptin or tocilizumab.
Locations: Barts and The London, The Christie NHS Foundation Trust Manchester, Churchill Hospital Oxford, Royal Marsden NHS Foundation Trust Sutton
ClinicalTrials.gov ID: NCT03869190
For people who have advanced or metastatic bladder cancer. Patients will receive a drug called LY3143921. This is an early study looking at the safety and ideal doses of the drug.
Locations: Belfast City Hospital, Western General Hospital Edinburgh, Beatson West of Scotland Cancer Centre Glasgow, Northern Centre for Cancer Care Newcastle Upon Tyne
ClinicalTrials.gov ID: NCT03096054
This is a study for people with metastatic or inoperable bladder cancer who test positive for the FGFR (Fibroblast Growth Factor Receptor) alteration biomarker. This study will be used to test the ideal dose of two drugs called erdafitinib and cetrelimab, as well as to test their safety and how well they work.
Locations: Addenbrooke's Hospital Cambridge, Colchester Hospital University, Royal Lancaster Infirmary, St Bartholomew's Hospital
ClinicalTrials.gov ID: NCT03473743
This is for people with muscle-invasive bladder cancer. This study is looking at the use of the drug nivolumab with chemotherapy.
Locations: Chelmsford, York, Glasgow, Lancaster, London, Oxford
ClinicalTrials.gov ID: NCT03661320
This study is for people who have advanced or metastatic bladder cancer, who have been previously treated with chemotherapy. Patients will receive a drug called atezolizumab. This is a study looking at how well this drug works in people with bladder cancer.
Locations: Barnet Hospital, Royal United Hospital Bath, Clatterbridge Cancer Centre Bebington, Heartlands Hospital Birmingham, East Lancashire Hospitals NHS Trust Burnley, Addenbrookes Hospital Cambridge, Velindre Cancer Centre Cardiff, Diana Princess of Wales Hospital Grimsby, Royal Surrey County Hospital Guildford, Northwick Park Hospital Harrow, Huddersfield Royal Infirmary, Hull Royal Infirmary, Airedale General Hospital Keighley, Royal Marsden Hospital Kingston upon Thames, St Bartholomew's Hospital London, Royal Free Hospital London, Guys and St Thomas Hospital London, Queen Elizabeth Hospital London, St George's Hospital London, Royal Marsden Hospital, Fulham London, Hammersmith Hospital London, Charing Cross Hospital London, Maidstone Hospital, The Christie Manchester, James Cook Hospital Middlesbrough, Freeman Hospital Newcastle upon Tyne, Nottingham City Hospital, Churchill Hospital Oxford, Royal Preston Hospital, Weston Park Hospital Sheffield, Royal Stoke University Hospital, Royal Marsden Hospital Sutton, Torbay Hospital, Royal Cornwall Hospital, Pinderfields General Hospital Wakefield, Great Western Hospitals Wiltshire, New Cross Hospital Wolverhampton, York Hospital
ClinicalTrials.gov ID: NCT03782207
This study is looking at the safety and tolerability of the drug MRx0518 in people with solid tumours at 30 days post-surgery. It is a phase 1 clinical trial and will look at the drug’s anti-cancer and immune system modulating properties. Patients will need to be amenable to surgical resection.
Location: Imperial College Healthcare NHS Trust
ClinicalTrials.gov ID: NCT03934827
The purpose of this observational study is to identify participants with bladder cancer and selected FGFR aberrations through molecular testing of their archival tumour tissue.
Locations: Colchester Hospital University NHS, Royal Devon & Exeter Hospital, Queen Alexandra Hospital Portsmouth, Royal Preston Hospital, The Clatterbridge Cancer Centre Wirral
ClinicalTrials.gov ID: NCT03955913
In this study researchers want to gather relevant information regarding the safety of BAY2416964 and how well the drug works in participants with a type of solid tumours that cannot be cured by currently available drugs. Researchers want to find the highest dose of BAY2416964 that participants could take without having too many side-effects, how the drug is tolerated and the way the body absorbs, distributes and gets rid of the study dug.
Locations: Royal Marsden NHS Trust Surrey, Beatson West of Scotland Cancer Centre Glasgow, Christie Hospital Manchester
ClinicalTrials.gov ID: NCT04069026
This is a study to evaluate the efficacy of giving infigratinib, as additional treatment following surgery in people with muscle-invasive bladder carcinoma and the FGFR3 biomarker. The study enrols subjects with either bladder cancer post radical cystectomy or upper tract urothelial cancer post distal ureterectomy and/or nephrectomy.
Location: Sarah Cannon Research Institute London
ClinicalTrials.gov ID: NCT04197986
This trial will look at a drug called SEA-TGT to find out whether it is safe for patients with solid tumours and lymphomas. It will study SEA-TGT to find out what its side effects are. It will also study whether SEA-TGT works to treat solid tumours and lymphomas.
Locations: The Royal Marsden Hospital Surrey
ClinicalTrials.gov ID: NCT04254107
This trial will look at a drug called SGN-B6A to find out whether it is safe for people who have solid tumours. It will study SGN-B6A to find out what its side effects are. It will also study whether SGN-B6A works to treat solid tumours.
Location: The Royal Marsden Hospital Surrey
ClinicalTrials.gov ID: NCT04389632
This is a study to evaluate HMBD-001 for the treatment of people with bladder cancer who test positive for the HER3 biomarker. The main aims are to find out the maximum dose of HMBD-001 that can be given safely to patients alone and in combination with other anti-cancer agents, more about the potential side effects of HMBD-001 and how these can be treated.
Locations: London, Oxford
ClinicalTrials.gov Identifier: NCT05057013
This study is for people with muscle-invasive or advanced bladder cancer. Its aim is to determine the safety, tolerability and effectiveness of an immunotherapy drug used in combination with radiotherapy. It is a phase 1 clinical trial, and will start with pembrolizumab prior to starting a course of radiotherapy.
Location: Royal Marsden NHS Foundation Trust
ClinicalTrials.gov ID: NCT02560636
Radical cystectomy (bladder removal) after bladder cancer necessitates surgical reconstruction to allow urine drainage. The current project will explore patient concerns, and the aspects of their lifestyles and values, that influence their choice of bladder reconstruction. It will also examine which of these concerns and values best predict satisfaction
Location: Swansea University
ClinicalTrials.gov ID: NCT03325231
This is a study for people with advanced bladder cancer who test positive for the FGFR biomarker. Patients will receive either chemotherapy, a drug called erdafitinib, or a drug called pembrolizumab. This study will test how well these drugs work in people with bladder cancer.
Locations: University Hospitals Bristol, St Bartholomew's Hospital London, Sarah Cannon Research Institute London, Charing Cross Hospital London, The Christie NHS Foundation Trust Manchester, Derriford Hospital Plymouth, University of Sheffield, Southampton General Hospital, Royal Marsden Hospital Sutton
ClinicalTrials.gov ID: NCT03390504
A study to determine the efficacy and safety of durvalumab in combination with tremelimumab and enfortumab vedotin or durvalumab in combination with enfortumab vedotin in people ineligible for chemotherapy undergoing radical cystectomy for muscle invasive bladder cancer
Soon recruiting in: Blackburn, Bristol, Gillingham, Glasgow, London.
ClinicalTrials.gov ID: NCT04960709
Get in touch
We’ve tried to make the information on this site as accurate as possible. Whilst we have support from medical professionals to review the general medical content of this site, please remember that only your medical team can give you specific advice about your symptoms or illness. Fight Bladder Cancer is a registered Charitable Incorporated Organisation in Scotland (SC051881), England and Wales (1198773), and was initially established as an unincorporated charity in England and Wales (1157763). It also operates in Northern Ireland.